Related Experiment Video
Updated: Jul 18, 2026

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan
Katsunada Fujimoto1, Masamichi Tomonaga, Shigenori Goto
1Fukuoka Medical Clinic, 6-18 Tenya-machi, Hakata-ku, Fukuoka, 812-0025, Japan. fujimoto@j-immunother.com
Background:
Immunotherapy is useful for the prevention of the post-operative recurrence of some types of cancer and, in combination with certain anticancer drugs, is expected to prolong survival time. However, the clinical efficacy of immunotherapy alone against advanced cancer has not yet been demonstrated.
Case Report:
A 67-year-old woman with ovarian cancer who had undergone post-operative adjuvant chemotherapy suffered from recurrent cancer in the lymph nodes. A partial response to adoptive immunotherapy and the administration of the biological response modifier, lentinan containing beta-glucan as the principal component, was maintained for five months without the use of chemotherapy.
Conclusion:
Adoptive immunotherapy with lentinan alone was potentially useful for the treatment of lymph node metastases from ovarian cancer.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Treatment Resistent Cancers
Treatment Resistant Cancers

